Association of MTHFR and PPARγ2 gene polymorphisms in relation to type 2 diabetes mellitus cases among north Indian population

Gene

Volumn 511, Issue 2, 2012, Pages 375-379

  Raza, Syed Tasleem ^a   Abbas, Shania ^a   Ahmed, Faisal ^a   Fatima, Jalees ^a   Zaidi, Zeashan Haider ^a   Mahdi, Farzana ^a  

^a Era's Lucknow Medical College and Hospital   (India)

Author keywords

Genetic polymorphism; MTHFR; PPAR 2; Type 2 diabetes mellitus

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; HUMANS; INDIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 84868197270     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.09.072     Document Type: Article

References (40)

1. Abdella N., Mojiminiyi O.A., Akanji A.O. Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease. Diabetes Res. Clin. Pract. 2000, 50:177-185.
2. Aguilar B., Rojas J.C., Collados M.T. Metabolism of homocysteine and its relationship with cardiovascular disease. J. Thromb. Thrombolysis 2004, 18:75-87. ([Online] Available: http://www.jn.nutrition.org).
3. Agullo Ortuno M.T., et al. Plasmatic homocysteine concentration and its relationship with complication associated to diabetes mellitus. Clin. Chim. Acta 2002, 326:105-112.
4. Altshuler D., et al. The common PPARγ Pro12Ala polymorphism in associated with decreased risk of type 2 diabetes. Nat. Genet. 2000, 26:76-80.
5. Amal M., et al. Methylenetetrahydrofolate reductase gene polymorphism and the risk of ischemic stroke in type 2 diabetic Egyptian patients. Glob. J. Health Sci. 2011, 3(2):162.
6. Ambrosch A., et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet. Med. 2001, 18:185-192.
7. Angeline T., et al. Homocysteine status and acute myocardial infarction among Tamilians. Indian J. Clin. Biochem. 2005, 20(1):18-20. ([Online] Available: http://www.medind.nic.in/iaf).
8. Audelin M., Genest J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001, 159:497-511. ([Online] Available: http://www.sciencedirect.com).
9. Auwerx J. PPARγ the ultimate thrifty gene. Diabetologia 1999, 42:1033-1049.
10. Balasubramanyam M., Mohan V. Current concepts of PPARγ signaling in diabetes mellitus. Curr. Sci. 2000, 79(10):1440-1445.
11. Barraz J.T., et al. Methylenetetrahydrofolate reductase gene polymorphism in diabetes and obesity. Mol. Biol. Rep. 2009, 37:105-109.
12. 2 gene with obesity in two Caucasian population. Diabetes 1998, 47:1806-1808.
13. Bostom A.G., et al. Hyperhomocysteinemia and traditional cardiovascular diseases risk factor in end stage renal disease patient on dialysis: a case-control study. Atherosclerosis 1995, 114:93-103.
14. Bouassida K.Z., et al. The peroxisome proliferated activated cell receptorφ2 (PPAR φ2)Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients. Diabetes Metab. 2005, 31:119-123.
15. Chico A., et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?. Diabetologia 1998, 41:684-693.
16. De Luis D.A., et al. Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res. Clin. Pract. 2002, 55:185-190.
17. 2associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 1998, 20:284-287.
18. Dehwah M.A.S., et al. Type 2 diabetes in Han Chinese in Hubei. J. Appl. Sci. 2008, 8(7):1235-1241.
19. Eikelboom J., et al. Association between high homocyst(e)ine and ischemic stroke due to large and small artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000, 31:1069-1075. ([Online] Available: http://www.ahajournals.org/cgi/). 10.1161/01.STR.31.5.1069.
20. Ek J., et al. Homozygosity of the Pro12Ala variant of the peroxisomes proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effect on body mass index in obese and lean Caucasian men. Diabetologia 1999, 42:892-895.
21. Errera F.I.V., et al. Effect of polymorphism of the MTHFR and APOE gene on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian population. Braz. J. Med. Biol. Res. 2006, 39:883-888.
22. Fajas L., et al. The organization, promoter analysis, and expression of the human PPARc gene. J. Biol. Chem. 1997, 272(30):18779-18789.
23. Florian B., et al. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 2006, 26:28-40.
24. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
25. Frosst P., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10:111-113.
26. Ghoussaini M., et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med. Genet. 2005, 6:11.
27. Hoogeveen E.K., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin dependent diabetes mellitus: a population-based study. Arterioscler. Thromb. Vasc. Biol. 1998, 18:133-138.
28. Masugi J., et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptorgamma 2 on thiazolidinedione-induced adipogenesis. Biochem. Biophys. Res. Commun. 2000, 268:178-182.
29. Mori H., et al. The Pro123Ala substitution in PPAR-g is associated with resistance to development of diabetes in the general population. Diabetes 2001, 50:891-894.
30. Mtiraoui N., et al. MTHFR C677T and A1298C gene polymorphism and hyperholnocysteinemia as risk factor of diabetic nephropathy in type 2 diabetes patients. Diabetes Res. Clin. Pract. 2006, 75:99-106.
31. Muller Y.L., et al. A functional variant in the peroxisome proliferator-activated receptor-2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003, 52:1864-1871.
32. Noiri E., et al. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care 2000, 23:260.
33. Ozmen B., et al. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann. Clin. Lab. Sci. 2002, 32(3):279-286. ([Online] Available: http://www.ncbi.nlm.nih.gov/pubmed/12175091).
34. Pollex R., et al. Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. Cardiovasc. Diabetol. 2005, 7:4-17. ([Online] Available: http://creativecommons.org).
35. Ralph C., Jacobsen D.W. Homocysteine in Health and Disease 2001, Cambridge University Press, Cambridge, UK.
36. Molecular Cloning; a Laboratory Manual 1989, 9.14-9.19. Cold Sping Harbor Laboratory Press, New York. 2nd ed. J. Sambrook, E.F. Frisch, T. Maniatis (Eds.).
37. Sun Jia-Zhong, et al. Polymorphism of the methylenetetrahydrofolate reductase gene association with homocysteine and ischemic stroke in type 2 diabetes. Neurol. India 2009, 57(5).
38. Wild S., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
39. Yen C.J., et al. Molecular scanning of the human peroxisomes proliferator activated receptor gamma (hPPARγ) gene in diabetic Caucasian: identification of a Pro12Ala PPARγ2 missense mutation. Biochem. Biophys. Res. Commun. 1997, 241:270-274.
40. Yilmaz H., et al. Methylenetetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J. Biochem. Mol. Biol. 2004, 37:234-238.